M4645 / EMD Serono - LARVOL DELTA

[VIRTUAL] M4645 is a potent and highly selective inhibitor of disease relevant cKIT mutations for the treatment of metastatic or recurrent GIST (AACR 2021) - "Currently approved 2L and 3L therapies sunitinib and regorafenib target these mutations only to some extent and show limited clinical benefit. Even with the recent approval of ripretinib as 4L treatment, a high unmet medical need remains for patients with imatinib resistance mutations in exon13/14...Compared to imatinib, M4645 induced prolonged anti-tumor response in a GIST model with a primary activating mutation of cKIT. In summary, the favorable profile and strong antitumor activity, particularly in GIST models expressing the V654A resistance mutation, suggests superiority of M4645 compared to currently available > 2L treatment options for unresectable metastatic or recurrent GIST patients."

Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Oncology • Sarcoma